

COVID-19 - Pipeline Insight, 2021

<https://marketpublishers.com/r/C1170260EED5EN.html>

Date: May 2021

Pages: 300

Price: US\$ 2,000.00 (Single User License)

ID: C1170260EED5EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "COVID-19 - Pipeline Insight, 2021," report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in COVID-19 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

COVID-19 Understanding

COVID-19: Overview

Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease causes respiratory illness (like the flu) with symptoms such as a cough, fever, and difficulty breathing. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Elderly people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. The COVID-19 virus is primarily transmitted through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. People can catch COVID-19 if they breathe in droplets from a person with

COVID-19 who coughs out or exhales droplets. It also spreads when a person touches a surface or objects that has the virus on it, and then touches their eyes, nose, or mouth.

Rapid and accurate detection of COVID-19 is crucial to control outbreaks in the community and in hospitals. Current diagnostic tests for coronavirus include reverse-transcription polymerase chain reaction (RT-PCR), real-time RT-PCR (rRT-PCR), and reverse transcription loop-mediated isothermal amplification (RT-LAMP). RT-LAMP has similar sensitivity to rRT-PCR, is highly specific and is used to detect MERS-CoV. COVID-19 is a new disease and there is limited information regarding risk factors for severe illness. Based on currently available information and clinical expertise, people of all ages can be infected by the novel coronavirus. Older people, and people with pre-existing medical conditions (such as asthma, diabetes, and heart disease) appear to be more vulnerable to becoming severely ill with the virus.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence COVID-19 R&D. The therapies under development are focused on novel approaches for COVID-19.

COVID-19 Emerging Drugs Chapters

This segment of the COVID-19 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

COVID-19 Emerging Drugs

Sotrovimab: Vir Biotechnology/ GlaxoSmithKline

VIR-7831 is a monoclonal antibody that has demonstrated the ability to neutralize SARS-CoV-2 live virus in vitro. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (also known as SARS), indicating that the epitope is highly conserved, which may make it more difficult for escape mutants to develop. VIR-7831 has been engineered to enhance bioavailability and have an extended half-life.

It is being developed by Vir Biotechnology in collaboration with GlaxoSmithKline. In May, 2021, The European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion for GlaxoSmithKline (GSK) and Vir Biotechnology's sotrovimab (VIR-7831) as early Covid-19 treatment.

VERU111: Veru Inc.

Sabizabulin, an oral, first-in-class alpha and beta tubulin inhibitor/cytoskeleton disruptor small molecule, for the treatment of COVID-19 patients at high risk for acute respiratory distress syndrome. Sabizabulin may have dual drug action as a broad antiviral agent and anti-inflammatory agent against COVID-19 infection. It is currently in Phase III stage of development and is being developed by Veru Inc.

Further product details are provided in the report

COVID-19: Therapeutic Assessment

This segment of the report provides insights about the different COVID-19 drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on COVID-19

There are approx. 150+ key companies which are developing the COVID-19. The companies which have their COVID-19 drug candidates in the most advanced stage, i.e. Preregistration include, Vir Biotechnology/ GlaxoSmithKline.

Phases

DelveInsight's report covers around 200+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

COVID-19 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

COVID-19: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses COVID-19 therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging COVID-19 drugs.

COVID-19 Report Insights

COVID-19 Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

COVID-19 Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing COVID-19 drugs?

How many COVID-19 drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for COVID-19?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the COVID-19 therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for COVID-19 and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Vir Biotechnology/ GlaxoSmithKline

Can-Fite Biopharma

AbbVie

Novartis

Tonix Pharmaceuticals

Molecular Partners

Veru Inc.

PTC Therapeutics

RedHill Biopharma

SAb Biotherapeutics

Adagio Therapeutics

Valneva

Novavax

Inovio Pharmaceuticals

VBI Vaccines

Rigel Pharmaceuticals

Translate Bio

Evelo Biosciences

Cocrystal Pharma

Icosavax

Atea Pharmaceuticals

NovaLead

Key Products

Sotrovimab

CF-101

ABBV-47D11

MAS-825

TNX 1800

MP-0420

MP0423

VERU-111

PTC-299

RHB-107

SAB-185

ADG20

VLA2001

NVX-CoV2373

INO-4800

VBI-2902

Fostamatinib

MRT5500

EDP-1815

CDI-45205

IVX-411

AT?527

NLP21

Contents

Introduction

Executive Summary

COVID-19: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

COVID-19– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

COVID-19 companies' collaborations, Licensing, Acquisition -Deal Value Trends

COVID-19 Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

VERU-111: Veru Inc.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

CF-101: Can-Fite Biopharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

ABBV-47D11: AbbVie

Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
Comparative Analysis
TNX-1800: Tonix Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
COVID-19 Key Companies
COVID-19 Key Products
COVID-19- Unmet Needs
COVID-19- Market Drivers and Barriers
COVID-19- Future Perspectives and Conclusion
COVID-19 Analyst Views
COVID-19 Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for COVID-19

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for COVID-19
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: COVID-19 - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/C1170260EED5EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C1170260EED5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970